11 completed, 2 recruiting, 1 unknown. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 11, Recruiting 2, Unknown 1 |
Follow Sleep Disorders, Circadian Rhythm: new trials by email Literature Review of Sleep Disorders, Circadian Rhythm trials Research Report on Sleep Disorders, Circadian Rhythm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant Tasimelteon, Placebo - Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Phase 3 | Recruiting | Vanda Pharmaceuticals | 60 | 2024-10-08 | 2024-11-22 |
| Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo - Excessive Sleepiness, Shift-work Disorder | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 520 | 2024-08-01 | 2026-07-24 |
| THRIVE Feasibility Trial Anesthetic technique Propofol TIVA, Anesthetic technique inhaled agent - Surgery--Complications, Anesthesia Complication | Phase 3 | Completed | Washington University School of Medicine | 300 | 2022-09-29 | 2023-11-24 |
| Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Tasimelteon, Placebo - Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Phase 3 | Completed | Vanda Pharmaceuticals | 43 | 2020-12-09 | 2026-10-09 |
| The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder Melatonin 0.5 MG, Dim Light Melatonin Onset (salivary) - Delayed Sleep Phase Syndrome | Phase 3 | Completed | University of Michigan | 44 | 2019-02-15 | 2022-11-25 |
| Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm Melatonin 4 mg Tablet - Diabetic Retinopathy, Melatonin | Phase 3 | Completed | Glostrup University Hospital, Copenhagen | 31 | 2018-03-27 | 2021-08-02 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers Melatonin 2mg, Placebo - Sleep Disorders, Circadian Rhythm | Phase 3 | Completed | Universitätsklinikum Hamburg-Eppendorf | 46 | 2015-01-01 | 2017-05-25 |
| Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception tasimelteon - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 200 | 2011-10-01 | 2015-04-21 |
| Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 20 | 2011-09-01 | 2014-10-10 |
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception tasimelteon - Non 24 Hour Sleep Wake Disorder | Phase 3 | Unknown | Vanda Pharmaceuticals | 140 | 2010-10-28 | 2024-04-03 |
| Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 136 | 2010-08-01 | 2014-10-16 |
| Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Armodafinil 150 mg/day, Placebo - Excessive Sleepiness, Shift Work Sleep Disorder | Phase 3 | Completed | Cephalon | 254 | 2004-03-01 | 2013-07-19 |
| Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder CEP-10953 (Armodafinil) - Narcolepsy, Sleep Apnea, Obstructive | Phase 3 | Completed | Cephalon | 328 | 2004-01-01 | 2013-07-19 |
Chronobiology Disorders (9) · Sleep Wake Disorders (7) · Blindness (4) · Disorders of Excessive Somnolence (4) · Dyssomnias (4) · Eye Diseases (4) · Nervous System Diseases (4) · Sleep Initiation and Maintenance Disorders (2) · Alzheimer Disease (1) · Cataplexy (1) · Cognitive Dysfunction (1) · Dementia (1) · Dementia, Vascular (1) · Depression (1)
Mental Disorders (14) · Occupational Diseases (14) · Dyssomnias (10) · Nervous System Diseases (10) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Sleep Wake Disorders (7) · Chronobiology Disorders (5) · Sensation Disorders (4) · Sleep Disorders, Intrinsic (4) · Vision Disorders (4) · Behavior (2) · Behavioral Symptoms (2) · Cardiovascular Diseases (2)
tasimelteon (6) · Melatonin (3) · Modafinil (2) · Tablets (1) · solriamfetol (1)
Vanda Pharmaceuticals (6) · Cephalon (2) · Axsome Therapeutics, Inc. (1) · Glostrup University Hospital, Copenhagen (1) · University of Michigan (1) · University of Pennsylvania (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Washington University School of Medicine (1)
United States (9) · Germany (3) · Austria (1) · Canada (1) · Denmark (1) · France (1) · Italy (1) · Russia (1) · Turkey (Türkiye) (1)
Leslie Swanson, Ph.D. (1) · Michael S Avidan, MBBcH (1) · Nancy A. Hodgson (1) · Rainer H Boeger, MD (1) · Sachin Kheterpal, MD (1) · Shakoor Ba-Ali (1)
PMID 26466871, PMID 19880686, PMID 33853394, PMID 34344312, PMID 37068889, PMID 38033548, PMID 38445651, PMID 41950401
2015 (1), R01NR015226 (1)